Literature DB >> 7006666

Cellular events leading to blister formation in bullous pemphigoid.

L Dubertret, B Bertaux, M Fosse, R Touraine.   

Abstract

Cellular events occurring in eight patients with bullous pemphigoid were studied by light and electron microscopy. Sections (0.5 micrometer) of large surface area, overlapping blisters and surrounding skin, were examined and correlated ultrastructural studies were performed on selected areas. The peroxidase contained in granules of neutrophils, eosinophils and young macrophages was visualized by incubation with diaminobenzidine and hydrogen peroxide. This cytochemical reaction was used as a marker to study the release of granule enzymes from these inflammatory cells. The release of such enzymes from eosinophils and occasionally from macrophages on the epidermal basement membrane (more precisely in the lamina lucida) was demonstrated in the skin surrounding the blisters in four patients. The release of these enzymes was also observed in the floor of the blisters in all eight patients. It is well known that these granules contain several proteolytic enzymes. These observations are therefore consistent with the proposal that proteolytic enzymes of eosinophils play a pathogenic role during the initial stages of blister formation in bullous pemphigoid.

Entities:  

Mesh:

Year:  1980        PMID: 7006666     DOI: 10.1111/j.1365-2133.1980.tb01683.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

1.  A major role for neutrophils in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; X Zhou; S J Swartz; J L Troy; J A Fairley; G O Till; L A Diaz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Increased immunoreactive interleukin-5 levels in blister fluids of bullous pemphigoid.

Authors:  H Endo; I Iwamoto; M Fujita; S Okamoto; S Yoshida
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

3.  Determination of tumor necrosis factor in blister fluids of bullous pemphigoid.

Authors:  H Takematsu; H Ohta; H Tagami
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

4.  Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid.

Authors:  E Schmidt; B Bastian; R Dummer; H P Tony; E B Bröcker; D Zillikens
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

5.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.

Authors:  L Borrego; B Maynard; E A Peterson; T George; L Iglesias; M S Peters; W Newman; G J Gleich; K M Leiferman
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

6.  Eosinophil granule proteins expressed in ocular cicatricial pemphigoid.

Authors:  A Heiligenhaus; J Schaller; S Mauss; S Engelbrecht; J E Dutt; C S Foster; K P Steuhl
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

7.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

8.  Alteration in the density, morphology, and biological properties of eosinophils produced by bullous pemphigoid blister fluid.

Authors:  M Miyasato; S Tsuda; M Kasada; K Iryo; Y Sasai
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

9.  92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen.

Authors:  M Ståhle-Bäckdahl; M Inoue; G J Guidice; W C Parks
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 10.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.